• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Humacyte Inc.

    5/14/26 4:31:38 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $HUMA alert in real time by email
    S-8 1 tm2614662d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on May 14, 2026

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE

    SECURITIES ACT OF 1933

     

     

     

    Humacyte, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware  85-1763759
    (State or other jurisdiction of incorporation or organization)  (I.R.S. Employer Identification No.)
        
    2525 East North Carolina Highway 54   
    Durham, NC  27713
    (Address of Principal Executive Offices)  (Zip Code)

     

    Humacyte, Inc. 2021 Long-Term Incentive Plan

    (Full title of the plan)

     

    Dale A. Sander

    Chief Financial Officer

    Humacyte, Inc.

    2525 East North Carolina Highway 54

    Durham, NC 27713

    (Name and address of agent for service)

     

    (919) 313-9633

    (Telephone number, including area code, of agent for service)

     

    Copy to:

    Kerry S. Burke

    Covington & Burling LLP

    One CityCenter

    850 Tenth Street, NW

    Washington, DC 20001

    (202) 662-6000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer o   Accelerated filer o
    Non-accelerated filer x   Smaller reporting company x
          Emerging growth company o

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is filed by Humacyte, Inc. (the “Company”) for the purpose of registering additional shares of its common stock, par value $0.0001 per share (the “Common Stock”), under the Company’s 2021 Long-Term Incentive Plan (the “Plan”).

     

    The number of shares of Common Stock reserved and available for issuance under the Plan will automatically increase on January 1 of each year, but not after August 26, 2031, in an amount equal to 5% of the total number of shares of the Company’s capital stock outstanding on December 31 of the preceding year, unless the board of directors of the Company acts prior to January 1 of a given year to provide that the increase for such year will be a lesser number of shares of Common Stock (the “Plan Provision”). Pursuant to an action by the board of directors of the Company, the number of shares of Common Stock available for issuance under the Plan was increased by 4,000,000 shares, effective January 1, 2026. This Registration Statement registers the offer and sale of the 4,000,000 additional shares of Common Stock that are available for issuance under the Plan as a result of the Plan Provision.

     

    Of the 23,410,314 shares of Common Stock currently authorized by the Plan, the Company has previously registered the offer and sale of 7,725,253 shares of Common Stock pursuant to the Company’s Registration Statement on Form S-8 filed on October 28, 2021 (Commission File No. 333-260561), 5,183,686 shares of Common Stock pursuant to the Company’s Registration Statement on Form S-8 filed on March 28, 2024 (Commission File No. 333-278296) and 6,501,375 shares of Common Stock pursuant to the Company’s Registration Statement on Form S-8 filed on March 31, 2025 (Commission File No. 333-286271) (collectively, the “Existing Plan Registration Statements”).

     

    Pursuant to General Instruction E to Form S-8 under the Securities Act of 1933, as amended, the contents of the Existing Plan Registration Statements, including any amendments thereto or filings incorporated therein by reference are incorporated herein by reference and made part of this Registration Statement. Any items in the Existing Plan Registration Statements not expressly changed hereby shall be as set forth in the applicable Existing Plan Registration Statement.

     

     

     

     

    PART II

     

    Information Required in the Registration Statement

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents (File No. 001-818382) previously filed with the Securities and Exchange Commission (the “SEC”) are hereby incorporated by reference:

     

    ·the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 27, 2026 (including the portions of the Company’s Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 28, 2026, incorporated by reference therein);

     

    ·the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 13, 2026;

     

    ·the Company’s Current Reports on Form 8-K (File No. 001-39532) (other than portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits accompanying such reports that are related to such items) filed on March 19, 2026, March 19, 2026, April 24, 2026 and May 8, 2026; and

     

    ·the description of the Company’s Common Stock contained in Exhibit 4.6 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 28, 2024, including any amendments or reports filed for the purposes of updating this description.

     

    All reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment which indicates that all securities registered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents, except as to specific sections of such statements as set forth therein.

     

    Unless expressly incorporated into this Registration Statement, a report furnished on Form 8-K (or any portion thereof so furnished) prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.

     

     

     

     

    Item 8. Exhibits.

     

    Exhibit Number.   Description
    4.1   Second Amended and Restated Certificate of Incorporation of Humacyte, Inc., as amended (incorporated by reference to Exhibit 3.1 to Humacyte, Inc.’s Current Report on Form 10-K, filed with the SEC on March 27, 2026).
         
    4.2   Amended and Restated By Laws of Humacyte, Inc. (incorporated by reference to Exhibit 3.2 to Humacyte, Inc.’s Current Report on Form 8-K, filed with the SEC on December 12, 2022).
         
    5.1*   Opinion of Covington & Burling LLP.
         
    23.1*   Consent of Covington & Burling LLP (included in Exhibit 5.1).
         
    23.2*   Consent of PricewaterhouseCoopers LLP.
         
    24.1*   Power of attorney (included on signature page).
         
    99.1   Humacyte, Inc. 2021 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.4 to Humacyte, Inc.’s Current Report on Form 8-K, filed with the SEC on August 27, 2021).
         
    107*   Filing Fee Table.

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, Humacyte, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina, on May 14, 2026.

     

      HUMACYTE, INC.
      ​
      By: /s/ Laura E. Niklason
      ​ Name: Laura E. Niklason, M.D., Ph.D.
      ​ Title: President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Laura E. Niklason and Dale A. Sander, and each of them severally, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons, in the capacities indicated on May 14, 2026.

     

    Signature   Title
         
    /s/ Laura E. Niklason   President, Chief Executive Officer and Director  
    Laura E. Niklason, M.D., Ph.D.   (Principal Executive Officer)
         
    /s/ Dale A. Sander   Chief Financial Officer, Chief Corporate Development Officer and Treasurer  
    Dale A. Sander   (Principal Financial and Accounting Officer)
         
    /s/ John Bamforth   Director
    John Bamforth    
         
    /s/ Emery N. Brown   Director
    Emery N. Brown, M.D., Ph.D.    
         
    /s/ Michael T. Constantino   Director
    Michael T. Constantino    
         
    /s/ Brady W. Dougan   Director
    Brady W. Dougan    
         
    /s/ C. Bruce Green   Director
    C. Bruce Green, M.D.    
         
    /s/ Keith Anthony Jones   Director
    Keith Anthony Jones, M.D.    
         
    /s/ Todd M. Pope   Director
    Todd M. Pope    
         
        Director
    Kathleen Sebelius    
         
    /s/ Diane Seimetz   Director
    Diane Seimetz    
         
    /s/ Max Wallace   Director
    Max Wallace, J.D.    
         
    /s/ Susan Windham-Bannister   Director
    Susan Windham-Bannister, Ph.D.    

     

     

     

    Get the next $HUMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HUMA

    DatePrice TargetRatingAnalyst
    8/27/2025$3.50Overweight
    Barclays
    5/14/2025$4.00Buy
    H.C. Wainwright
    12/20/2024$12.00 → $15.00Buy
    H.C. Wainwright
    12/11/2023$6.00Buy
    H.C. Wainwright
    8/14/2023$2.75 → $3.50Underweight → Neutral
    Piper Sandler
    6/22/2023$6.00Overweight
    Cantor Fitzgerald
    5/16/2022$10.00 → $4.00Overweight → Underweight
    Piper Sandler
    10/29/2021$17.00Outperform
    Cowen & Co.
    More analyst ratings

    $HUMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sebelius Kathleen bought $50,000 worth of shares (56,818 units at $0.88), increasing direct ownership by 62% to 148,025 units (SEC Form 4)

    4 - Humacyte, Inc. (0001818382) (Issuer)

    5/20/26 4:33:09 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Constantino Michael T. bought $9,840 worth of shares (11,000 units at $0.89), increasing direct ownership by 33% to 43,950 units (SEC Form 4)

    4 - Humacyte, Inc. (0001818382) (Issuer)

    5/20/26 4:32:09 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CFO and Chief Corp. Dev. Off Sander Dale A. sold $41,147 worth of shares (45,887 units at $0.90) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 267,213 units (SEC Form 4) to satisfy tax liability

    4 - Humacyte, Inc. (0001818382) (Issuer)

    5/20/26 4:31:20 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HUMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Humacyte with a new price target

    Barclays initiated coverage of Humacyte with a rating of Overweight and set a new price target of $3.50

    8/27/25 8:22:05 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Humacyte with a new price target

    H.C. Wainwright resumed coverage of Humacyte with a rating of Buy and set a new price target of $4.00

    5/14/25 11:33:51 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright reiterated coverage on Humacyte with a new price target

    H.C. Wainwright reiterated coverage of Humacyte with a rating of Buy and set a new price target of $15.00 from $12.00 previously

    12/20/24 8:28:06 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HUMA
    SEC Filings

    View All

    SEC Form S-8 filed by Humacyte Inc.

    S-8 - Humacyte, Inc. (0001818382) (Filer)

    5/14/26 4:31:38 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Humacyte Inc.

    10-Q - Humacyte, Inc. (0001818382) (Filer)

    5/13/26 4:30:47 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Humacyte Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Humacyte, Inc. (0001818382) (Filer)

    5/8/26 4:30:16 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HUMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access

    - Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually -  - The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle cell repopulation despite repeated cannulations - - Humacyte anticipates that top-line interim results from its ongoing V012 Phase 3 study in dialysis access will be available for reporting in June - DURHAM, N.C., May 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of research providing evidence of self-repair of

    5/26/26 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs

    - Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospitals – - SAC awards require intensive product and value analysis vetting by a surgical committee and streamline the approval process by individual hospitals - DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that Symvess is now under contract with the with Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs (VA). The SAC SING (Surgical Implant – Next Generation) contract makes Symvess more e

    5/20/26 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update

    - Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer -  - First quarter sales of Symvess® were $0.5 million in 2026 compared to $0.1 million in 2025 - - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia - - Announced Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess for Vascular Injury Repair - - U.S. Department of Defense funding for procurement of bioengineered blood vessels - - Major milestone upcoming: Top-line interim results from V012 Phase 3 study in hemodialysis access - -Confe

    5/13/26 7:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HUMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sebelius Kathleen bought $50,000 worth of shares (56,818 units at $0.88), increasing direct ownership by 62% to 148,025 units (SEC Form 4)

    4 - Humacyte, Inc. (0001818382) (Issuer)

    5/20/26 4:33:09 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Constantino Michael T. bought $9,840 worth of shares (11,000 units at $0.89), increasing direct ownership by 33% to 43,950 units (SEC Form 4)

    4 - Humacyte, Inc. (0001818382) (Issuer)

    5/20/26 4:32:09 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Commercial Officer Scheessele William John bought $9,999 worth of shares (6,493 units at $1.54), increasing direct ownership by 42% to 22,018 units (SEC Form 4)

    4 - Humacyte, Inc. (0001818382) (Issuer)

    4/15/25 4:03:35 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HUMA
    Financials

    Live finance-specific insights

    View All

    Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

    DURHAM, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter ended March 31, 2026 on Wednesday, May 13, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update. TitleHumacyte 2025 First Quarter Financial Results and Corporate UpdateDateMay 13, 2026Time8:00 a.m. Eastern TimeConference Details1-877-704-4453 (U.S. Investors)1-201-389-0920 (International Investors)13760221 (Conference ID)Call

    5/8/26 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026

    DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter and year ended December 31, 2025 on Friday March 27, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update. TitleHumacyte 2025 Fourth Quarter and Year End Financial Results and Corporate UpdateDateMarch 27, 2026Time8:00 a.m. Eastern TimeConference Details1-877-704-4453 (U.S. Investors)1-201-389-0920 (International Investors)1

    3/23/26 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

    - Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement -  - Major advances in pipeline as Humacyte moves closer to planned BLA filing in dialysis and first-in-human studies in cardiac bypass graft surgery – – IND submitted to the FDA for the CABG indication – - Symvess™ and pipeline programs highlighted in multiple scientific publications and presentations - - Conference call today at 8:00 am ET - DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercia

    11/12/25 7:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HUMA
    Leadership Updates

    Live Leadership Updates

    View All

    Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer

    - Distinguished vascular surgeon brings decades of clinical experience, innovation, and leadership to new role at cutting-edge biotech manufacturer - - Appointment brings important surgical experience and perspective to Humacyte's corporate leadership team as clinical adoption of Symvess® ramps up and pipeline indications move toward planned approval - DURHAM, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Todd E. Rasmussen, M.D., has joined the company as Chief Surgical Officer. In this role, Dr. Rasmusse

    5/12/26 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Humacyte Appoints Jim Mercadante as Chief Commercial Officer

    – Industry veteran with more than 25 years of experience will lead next phase of biotech company's commercial expansion – – Seasoned medtech commercial leader brings extensive field-specific success in vascular and cardiothoracic surgery markets – – Appointment strengthens commercial leadership as Symvess® (acellular tissue engineered vessel-tyod) market launch accelerates and pipeline advances toward planned BLA filing in dialysis – DURHAM, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the appointment of Jim Merc

    4/22/26 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Humacyte Appoints Rick McElheny as Senior Vice President of Business Development

    - Mr. McElheney brings more than 15 of years' experience in corporate development and alliance management at biopharma companies. -  - He will work with the Company's leadership team to expand corporate collaborations to accelerate the development and commercialization of Humacyte's broad pipeline - DURHAM, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has appointed Rick McElheny to the role of Senior Vice President of Business Development. Mr. McElheny will work with the Company's leadership team to expan

    3/26/26 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HUMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Humacyte Inc.

    SC 13D/A - Humacyte, Inc. (0001818382) (Subject)

    11/20/24 7:10:08 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Humacyte Inc.

    SC 13D/A - Humacyte, Inc. (0001818382) (Subject)

    11/18/24 4:10:14 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Humacyte Inc.

    SC 13D/A - Humacyte, Inc. (0001818382) (Subject)

    9/3/24 4:11:41 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care